Influenza Ha Vaccine Articles & Analysis
22 news found
With 18 known HA subtypes (H1-H18) and 11 NA subtypes (N1-N11), influenza A viruses pose a challenge to global health, particularly seasonal subtypes such as H1N1 and H3N. ...
Vaccines protect against a range of diseases, including measles, polio, diphtheria, tetanus, meningitis, influenza and cancer. ...
ByNuvonis
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a ...
ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree. ImmunAdd is undertaking the development of IA-05 in collaboration with several biopharma ...
Australian vaccine technology company BioDiem Ltd (“BioDiem”) announced that effective today, Mr Hugh Morgan AC, will step down from his non-executive director roles on the boards of BioDiem and its subsidiary, Opal Biosciences Ltd (“Opal”). Mr Hugh Morgan AC has been chairman of BioDiem since 2005 and is a major shareholder of the ...
If VOLT elects not to exercise its option, Cancer Research UK will have the right to take the programme forward in all cancer indications. Unlike preventative vaccines, such as the influenza vaccine, which is given to healthy people to protect them against future disease, VTP-600 is given to people who already have lung cancer. ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases ...
(“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella (“MR”) vaccine. ...
It potentially offers broad immunity against 100% of flu pandemics, 100% of animal influenzas and 80% of seasonal flu cases. The idea of a universal flu vaccine is not entirely novel. ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative ...
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global ...
For instance, Middle East Respiratory Syndrome (MERS), a virus that initially spread to humans from infected camels kept as livestock, has an average mortality rate of 35%. And the Nipah virus (which has seen documented transmission to humans from both pigs and bats) carries a mortality rate as high as 75%. ...
EnGen Bio is an early stage biotechnology company pioneering a new approach to preventing and treating influenza, with the goal of an effective, easy-to-manufacture, shelf-stable universal flu vaccine that should confer long-term immunity to all Type A influenza strains—including all flu pandemics. ...
” “As the COVID-19 pandemic continues to spread around the world, there is an urgent need to develop a vaccine to fight this global crisis and we are proud to partner with BlueWillow to create an intranasal vaccination that has the potential to save human lives,” said Charles Chen, CEO of MVC. “While there ...
AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. ...
(Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s technology, which has already been successfully evaluated in clinical studies including a Phase 1 trial of an ...
Osivax develops a clinical-stage pipeline of vaccines and immunotherapies based on the oligoDOM® technology. oligoDOM® is a pro-immunogenic antigen reengineering technology which has been developed over the last 15 years by Imaxio. ...
Imaxio, a biotech company specializing in immunology, announces today that it has received scientific advice from the European Medicines Agency (EMA) for IMX836, its vaccine candidate dedicated to the prevention of influenza in humans. This first scientific advice reinforces Imaxio’s plan to start, by early 2018, a phase I clinical trial ...
Imaxio, a biotech company specialized in immunology, announces today having received from the USPTO (United States Patent and Trademark Office) notices of allowance for two of its latest patent applications. Submitted in 2012 and 2013, and respectively entitled “Modified coiled-coil type proteins having improved properties” and “Influenza nucleoprotein vaccines”, these ...
Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded a funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project: “leveraging On t-cell immune resPonse To Improve influenza VACcines”. The ...